CogState Stock

CogState ROE

The Return on Equity (ROE) of CogState (CGS.AX) as of Sep 3, 2026 is 21.18 %. In the previous year, Return on Equity (ROE) was 13.32 % — a change of 59.03% (higher).

ROE

21.18 %

YoY

59.03%

Last updated:

In 2026, CogState's return on equity (ROE) was 21.18 %, a 59.03% increase from the 13.32 % ROE in the previous year.

The CogState ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
-4.84 USD
Jan 1, 2019
-24.68 USD
Jan 1, 2020
-12.63 USD
Jan 1, 2021
24.02 USD
Jan 1, 2022
22.84 USD
Jan 1, 2023
9.47 USD
Jan 1, 2024
13.32 USD
Jan 1, 2025
21.18 USD
The CogState ROE history
YEARROEYoY
21.18 %+59.03%
13.32 %+40.69%
9.47 %-58.56%
22.84 %-4.93%
24.02 %-290.17%
-12.63 %-48.81%
-24.68 %+409.59%
-4.84 %-16.57%
-5.80 %-130.31%
19.15 %-138.27%
-50.05 %+72.01%
-29.10 %
Access this data via the Eulerpool API

CogState Stock analysis

What does CogState do? CogState Ltd is an Australian company specializing in the development of innovative cognitive tests. The company was founded in 1999 and is based in Melbourne, Australia. It conducts computer-based cognitive tests to gather information about the cognitive functioning of patients and athletes. The CogState tests are specifically designed to measure cognitive abilities in areas such as perception, reaction time, memory, and attention. The business model of CogState is based on the development, marketing, and sale of cognitive test products. The company generates a significant portion of its revenue through licensing its tests to pharmaceutical and biotech companies that want to test their medications or therapies more effectively. CogState also has a strong presence in the sports industry, offering its tests to sports teams and individual athletes. CogState was founded in 1999 by Paul Maruff, a neuropsychologist, who was searching for better and more effective ways to conduct cognitive tests. Initially, the tests developed by CogState were exclusively for medical research, but it was quickly discovered that they could be useful in other areas as well. In 2004, Richard Kimber joined the company as CEO and Chairman, bringing his experience from the biotechnology industry. CogState offers a variety of cognitive tests for various applications, including clinical trials, sports performance analysis, and brain injury treatment. The tests are licensed by different companies and organizations that use them to test the effects of medications and therapies on cognitive functions or to assess performance and injuries in sports. One example of a CogState product is the AX Continuous Tracker Test. This test was developed for clinical use and allows for continuous and accurate measurement of cognitive functions in patients with psychiatric and neurological disorders. Another application is the SPARQ test for athletes, which allows for the measurement and improvement of athletes' cognitive abilities. In summary, CogState Ltd is a leading company in the field of cognitive tests. The company specializes in developing innovative cognitive tests for the specific requirements of pharmaceutical and biotech companies, as well as sports organizations. The tests are used worldwide by various organizations and have a significant impact on the treatment of psychiatric and neurological disorders, as well as performance and injury analysis in sports. CogState is one of the most popular companies on Eulerpool.

ROE Details

Decoding CogState's Return on Equity (ROE)

CogState's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing CogState's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

CogState's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in CogState’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about CogState stock

Return on Equity (ROE) of CogState is 21.18 % in 2026.

Return on Equity (ROE) of CogState changed from 13.32 % to 21.18 %, representing a 59.03% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) CogState since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s CogState with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

Profitability — CogState

All Key Metrics — CogState